News | September 02, 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Subscribe To Our Newsletter & Stay Updated
